


Examining the efficacy of lispro in postprandial glucose control for diabetes

August 29 2022



(a) Mean HbA_{1c} during lead-in and 26-week treatment. Data are mean at screening and LSM (\pm SE) for all other time points. Noninferiority of URLi versus insulin lispro was shown in change of HbA_{1c} from baseline to week 26. (b) LSM post-prandial glucose excursions at weeks 26 during mixed-meal tolerance tests. Postprandial glucose excursions were improved significantly in patients treated with URLi compared with insulin lispro across all time points from 30 min to 240 min. Credit: Science China Press

Despite the range of available antihyperglycemic therapies, 57%–68% of Chinese patients with T2D fail to attain glycated hemoglobin A_{1c} (HbA_{1c}) target levels of

Citation: Examining the efficacy of lispro in postprandial glucose control for diabetes (2022, August 29) retrieved 26 July 2024 from <https://medicalxpress.com/news/2022-08-efficacy-lispro-postprandial-glucose-diabetes.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.